Table 1 Clinical trials in the context of SFKs. Data collected from clinicaltrials.gov on 10th Jan 2023
From: FYN: emerging biological roles and potential therapeutic targets in cancer
Inhibitor/Drug | Condition(s) | Phase | Clinical Trials ID | Refs |
|---|---|---|---|---|
of trial | ||||
Saracatinib | prostate cancer | II | NCT01267266 | [147] |
Dasatinib | melanoma | II | NCT00700882 | [148] |
JNJ-26483327 | solid tumors | I | NCT00676299 | [149] |
TPX-0046 | Non Small Cell Lung Cancer | I, II | NCT04161391 | NA |
| Â | Medullary Thyroid Cancer | Â | Â | Â |
| Â | RET Gene Mutation Metastatic Solid Tumor | Â | Â | Â |
| Â | Advanced Solid Tumors | Â | Â | Â |
AZD0424 | Advanced Solid Tumors | I | NCT01668550 | [150] |
Saracatinib | Small Cell Lung Cancer | II | NCT00528645 | [151] |
TPX-0022 | Advanced NSCLC, Gastric Cancer or Solid Tumors | I, II | NCT03993873 | NA |
AZD0530 | Non Small Cell Lung Cancer, Epithelial Ovarian Cancer | I | NCT01000896 | NA |
Ponatinib | Acute Lymphoblastic Leukemia | II | NCT05306301 | NA |
Bosutinib | Advanced Breast Cancer | I | NCT03854903 | NA |
KX2-391 | Bone-Metastatic, Castration-Resistant Prostate Cancer | II | NCT01074138 | [152] |
Repotrectinib | Locally Advanced Solid Tumors/Metastatic Solid Tumors | I, II | NCT03093116 | [153] |
ON123300 | Solid Tumors | I | NCT04739293 | NA |